A micro costing analysis of the development of a primary care intervention to improve the uptake of diabetic retinopathy screening.

Susan Ahern, Fiona Riordan, Aileen Murphy, John Browne, Patricia M Kearney, Susan M Smith, Sheena M McHugh
{"title":"A micro costing analysis of the development of a primary care intervention to improve the uptake of diabetic retinopathy screening.","authors":"Susan Ahern,&nbsp;Fiona Riordan,&nbsp;Aileen Murphy,&nbsp;John Browne,&nbsp;Patricia M Kearney,&nbsp;Susan M Smith,&nbsp;Sheena M McHugh","doi":"10.1186/s13012-021-01085-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The application of economic analysis within implementation science is still developing and the cost of intervention development, which differs markedly from the costs of initial implementation and maintenance, is often overlooked. Our aim was to retrospectively cost the development of a multifaceted intervention in primary care to improve attendance at diabetic retinopathy screening.</p><p><strong>Methods: </strong>A retrospective micro costing of developing the intervention from the research funder perspective was conducted. It was based on a systematic intervention development process involving analysis of existing audit data and interviews with patients and healthcare professionals (HCPs), conducting consensus meetings with patients and HCPs, and using these data together with a rapid review of the effectiveness of interventions, to inform the final intervention. Both direct (non-personnel, e.g. travel, stationary, room hire) and indirect (personnel) costs were included. Data sources included researcher time logs, payroll data, salary scales, an online financial management system, invoices and purchase orders. Personnel involved in the intervention development were consulted to determine the activities they conducted and the duration of their involvement. Sensitivity and scenario analyses were conducted to estimate uncertainty around parameters and scope.</p><p><strong>Results: </strong>The total cost of intervention development (July 2014-January 2019) was €40,485 of which 78% were indirect (personnel) costs (€31,451). In total, personnel contributed 1368 h to intervention development. Highest cost activities were the patient interviews, and consensus process, contributing 23% and 34% of the total cost. Varying estimated time spent on intervention development activities by + 10% increased total intervention development cost by 6% to €42,982.</p><p><strong>Conclusions: </strong>Our results highlight that intervention development requires a significant amount of human capital input, combining research experience, patient and public experience, and expert knowledge in relevant fields. The time committed to intervention development is critical but has a significant opportunity cost. With limited resources for research on developing and implementing interventions, capturing intervention development costs and incorporating them as part of assessment of cost-effective interventions, could inform research priority and resource allocation decisions.</p>","PeriodicalId":417097,"journal":{"name":"Implementation Science : IS","volume":" ","pages":"17"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13012-021-01085-4","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Implementation Science : IS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13012-021-01085-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: The application of economic analysis within implementation science is still developing and the cost of intervention development, which differs markedly from the costs of initial implementation and maintenance, is often overlooked. Our aim was to retrospectively cost the development of a multifaceted intervention in primary care to improve attendance at diabetic retinopathy screening.

Methods: A retrospective micro costing of developing the intervention from the research funder perspective was conducted. It was based on a systematic intervention development process involving analysis of existing audit data and interviews with patients and healthcare professionals (HCPs), conducting consensus meetings with patients and HCPs, and using these data together with a rapid review of the effectiveness of interventions, to inform the final intervention. Both direct (non-personnel, e.g. travel, stationary, room hire) and indirect (personnel) costs were included. Data sources included researcher time logs, payroll data, salary scales, an online financial management system, invoices and purchase orders. Personnel involved in the intervention development were consulted to determine the activities they conducted and the duration of their involvement. Sensitivity and scenario analyses were conducted to estimate uncertainty around parameters and scope.

Results: The total cost of intervention development (July 2014-January 2019) was €40,485 of which 78% were indirect (personnel) costs (€31,451). In total, personnel contributed 1368 h to intervention development. Highest cost activities were the patient interviews, and consensus process, contributing 23% and 34% of the total cost. Varying estimated time spent on intervention development activities by + 10% increased total intervention development cost by 6% to €42,982.

Conclusions: Our results highlight that intervention development requires a significant amount of human capital input, combining research experience, patient and public experience, and expert knowledge in relevant fields. The time committed to intervention development is critical but has a significant opportunity cost. With limited resources for research on developing and implementing interventions, capturing intervention development costs and incorporating them as part of assessment of cost-effective interventions, could inform research priority and resource allocation decisions.

初级保健干预发展的微观成本分析,以提高糖尿病视网膜病变筛查的吸收。
背景:经济分析在实施科学中的应用仍在发展中,干预措施开发的成本与最初实施和维护的成本明显不同,经常被忽视。我们的目的是回顾性分析在初级保健中开展多方面干预以提高糖尿病视网膜病变筛查的出勤率。方法:从研究资助者的角度对开发干预措施进行回顾性微观成本核算。它基于一个系统的干预发展过程,包括对现有审计数据的分析和对患者和卫生保健专业人员(HCPs)的访谈,与患者和卫生保健专业人员进行共识会议,并将这些数据与干预措施有效性的快速审查一起使用,以告知最终的干预措施。直接(非人员,如旅行、文具、房间租金)和间接(人员)费用均包括在内。数据来源包括研究人员时间日志、工资数据、工资等级、在线财务管理系统、发票和采购订单。与参与干预发展的人员进行协商,以确定他们进行的活动和参与的时间。进行敏感性和情景分析,以估计参数和范围周围的不确定性。结果:2014年7月至2019年1月干预开发总成本为40485欧元,其中78%为间接(人员)成本(31451欧元)。总的来说,工作人员为干预措施的发展贡献了1368小时。成本最高的活动是患者访谈和共识过程,分别占总成本的23%和34%。在干预开发活动上花费的估计时间增加10%,使干预开发总成本增加6%,达到42,982欧元。结论:我们的研究结果强调,干预开发需要大量的人力资本投入,结合研究经验、患者和公众经验以及相关领域的专家知识。投入干预措施开发的时间至关重要,但有很大的机会成本。由于开发和实施干预措施的研究资源有限,捕捉干预措施开发成本并将其纳入成本效益干预措施评估的一部分,可以为研究重点和资源分配决策提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信